基质细胞衍生因子-1质粒治疗外周动脉疾病(STOP-PAD)试验:6个月结果
STOP-PAD是一项多中心、随机、双盲、安慰剂对照的2B期试验,纳入109例Rutherford 5或6级慢性肢体威胁性缺血(CLTI)患者,在膝下动脉血运重建成功后分别接受8mg或16mg基质细胞衍生因子-1质粒肌肉注射或安慰剂。6个月时,三组完全伤口愈合率分别为31%、33%和33%,主要不良肢体事件(MALE)发生率分别为24%、29%和11%,组间无显著差异。结论认为血运重建联合生物治疗未能改善CLTI的6个月结局。
要点
- 在血运重建成功后,SDF-1质粒肌肉注射未提高6个月完全伤口愈合率。
- 6个月MALE发生率在安慰剂组24%、8mg组29%、16mg组11%,未显示显著降低。
- 三组趾臂指数较基线均有统计学显著增加,但未转化为临床获益。
核心结论
- 血运重建联合生物治疗(SDF-1质粒)未能改善CLTI患者6个月结局。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的2B期STOP-PAD试验(NCT02544204)。
- 随机纳入109例(平均年龄71岁;68例男性)Rutherford 5或6级CLTI且近期血运重建成功后足部灌注持续受损的患者。
- 患者接受8mg(n=34)或16mg(n=36)非病毒DNA质粒肌肉注射或安慰剂(n=34)。
主要发现
- 6个月完全伤口愈合率:安慰剂组31%、8mg组33%、16mg组33%。
- 6个月MALE发生率:安慰剂组24%、8mg组29%、16mg组11%。
- 各组趾臂指数从基线至6个月均有统计学显著增加。
- 6个月期间6例(6%)死亡,24例(23%)截肢(仅4例(4%)为大截肢)。
关键数值与推荐
- 主要疗效终点为独立伤口核心实验室评估的6个月伤口愈合评分。
- 主要安全终点为6个月MALE,即大截肢+临床驱动的靶病变血运重建复合终点。
临床怎么用
- 对于血运重建成功后的CLTI患者,不应常规使用SDF-1质粒肌肉注射以改善伤口愈合或降低MALE。
- 趾臂指数的改善未必转化为临床获益,需综合评估。
局限性
- 样本量较小(109例),可能不足以检测组间差异。
- 仅报告6个月结果,缺乏长期疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To present the 6-month results of the Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients with Peripheral Artery Disease (STOP-PAD) trial. The trial was an attempt to alter the course of chronic limb-threatening ischemia (CLTI) with a biological agent vs placebo after successful arterial revascularization at or below the knee. Materials and Methods: The multicenter, randomized, double-blinded, placebo-controlled, phase 2B STOP-PAD trial (ClinicalTrials.gov identifier NCT02544204) randomized 109 patients (mean age 71 years; 68 men) with Rutherford category 5 or 6 CLTI and evidence of persistent impaired forefoot perfusion following recent successful revascularization to 8- (n=34) or 16-mg (n=36) intramuscular injections of a non-viral DNA plasmid-based treatment vs placebo (n=34). The primary efficacy outcome was the 6-month wound healing score evaluated by an independent wound core laboratory; the primary safety endpoint was major adverse limb events (MALE), a composite of major amputation plus clinically-driven target lesion revascularization at 6 months. Results: Only one-third of the patients had complete wound healing at 6 months in the placebo (31%), 8-mg injection (33%), and 16-mg injection (33%) groups. In addition, the observed increase in the toe-brachial index from baseline to 6 months was statistically significant in each group; however, this did not result in lower rates of MALE at 6 months (24% in the placebo, 29% in the 8-mg injection, and 11% in the 16-mg injection groups). During the 6-month period, 6 patients (6%) died, and 24 patients (23%) had an amputation [only 4 (4%) major]. Conclusion: Combining revascularization and biological therapy failed to improve outcomes in CLTI at 6 months. STOP-PAD has provided insights for future trials to evaluate biological therapy.
引用
- Hammad TA, Rundback J, Bunte M, et al. Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients With Peripheral Artery Disease (STOP-PAD) Trial: Six-Month Results. J Endovasc Ther. 2020. PMID: 32419594. doi:10.1177/1526602820919951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。